ABSTRACT
Basing on computer processing of 126 primary clinical and laboratory parameters obtained from 92 patients with myelodysplasia and using multifactorial regression analysis, the authors have developed prognostic models of life span and probability of transformation into acute leukemia. The model of life span enabled recognition of 3 prognostic groups of myelodysplasia patients: of high (median 10 months), moderate (median 22 months) and low (median 35 months) risk. This makes it possible to prognosticate the disease and assume optimal therapeutic policy.
Subject(s)
Myelodysplastic Syndromes/mortality , Adult , Aged , Aged, 80 and over , Biopsy, Needle , Bone Marrow/pathology , Disease Progression , Female , Humans , Male , Middle Aged , Multivariate Analysis , Myelodysplastic Syndromes/pathology , Myelodysplastic Syndromes/therapy , Probability , Prognosis , Regression Analysis , Remission Induction , Risk FactorsABSTRACT
Hyperferremia is shown to affect antioxidant system of the body, oxidation-reduction reactions in the cells seen as shifts in lymphocyte chemiluminescence. Dynamic changes in lymphocyte chemiluminescence reflect the level of hyperferremia.
Subject(s)
Iron/blood , Lymphocytes/metabolism , Antioxidants , Combined Modality Therapy , Deferoxamine/therapeutic use , Dose-Response Relationship, Drug , Ferritins/pharmacology , Free Radicals/blood , Hemochromatosis/blood , Hemochromatosis/therapy , Humans , Iron/pharmacology , Luminescent Measurements , Lymphocyte Activation/drug effects , Lymphocytes/drug effects , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/therapy , Plasmapheresis , Transferrin/analysisSubject(s)
Anemia, Refractory , Myelodysplastic Syndromes/classification , Myelodysplastic Syndromes/diagnosis , Anemia, Refractory/classification , Anemia, Refractory/diagnosis , Anemia, Refractory/genetics , Anemia, Refractory/pathology , Anemia, Refractory, with Excess of Blasts/diagnosis , Anemia, Refractory, with Excess of Blasts/genetics , Anemia, Refractory, with Excess of Blasts/pathology , Bone Marrow/pathology , Chromosome Aberrations , Diagnosis, Differential , Humans , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology , Risk FactorsABSTRACT
The efficacies of Coombs' test and the polybrene test, heretofore not used in this country, for the diagnosis of autoimmune hemolytic anemias are compared in examinations of 27 donors and 62 patients with this condition. The results evidence a high efficacy of the polybrene test. The test is simple and available for wide use at clinical laboratories.